Bringing groundbreaking products to market that improve patient well-being is always top of mind for medtech and life science startups. This requires an all-hands-on-deck approach where every last piece of available resource is dedicated to the business' core operations. At the same time, monitoring backend processes like finance management and human resources (HR) is essential to ensuring business continuity. While the task may seem daunting, Murdock Martell—a boutique consulting firm—makes it a cakewalk. The company specializes in finance, accounting and HR services, guiding startups and emerging companies from seed funding to exit. It also serves various technology sectors, including AI, robotics and semiconductors, offering customized solutions. Founders are often stretched thin during a startup's early stages. Murdock Martell helps them offload noncore functions and offers essential operational support by simplifying their financial processes. This includes putting together financial statements, providing assistance in cash management and giving insights on the cash burn rate to help companies understand how long their funds will last. These offerings improve the client’s efficiency, leading to financial stability. “We help the founders put together a very simplistic set of financials, handle ongoing reporting and assist them with their business needs,” says Claire Martell, CEO. Once a startup begins to grow, hiring becomes a priority. Establishing a strong HR infrastructure is necessary to recruit and retain talented professionals for long-term success and ensure compliance with legal requirements. The company’s dedicated HR resources are perfectly equipped to address these requirements. Once these companies mature and achieve regulatory approvals from the FDA, they transition from development to commercialization. As companies scale up operations and begin full production, they need efficient inventory tracking, management and supply chain operations to ensure consistent cash flow and meet the lead times to support revenue growth. Rather than moving forward with commercialization, some companies even opt for a sale after the FDA approval. Murdock Martell supports these clients with due diligence, helping them meet the expectations of investors, regulators and buyers..

Who has fully realized that history is not contained in thick books but lives in our very blood?” This excerpt from Carl Jung’s work feels more relevant than ever as the world contends with the impact of synthetic chemicals in agriculture. As a result, age-old organic farming practices are being revisited, and answers are often found in humanity’s ancient past. Seeking to bridge this ancient wisdom with modern science, Robert H. Faust founded Faust Bio-Agricultural Services, Inc (BioAg), aiming to demystify concepts like biodynamics and bring regenerative practices back to the forefront. BioAg transmuted the rediscovered knowledge to provide the agricultural sector with an alternative viable technology called biostimulants. It leads the organic biostimulant manufacturing sector, allowing cultivators to grow plants efficiently and reach their genetic potential. “Unlike fertilizers and other conventional chemicals, our biostimulants target the nucleus of the cell to increase growth and disease resistance,” says Faust, founder and president. BioAg frees farmers from using chemicals through a complete biostimulant package. It allows them to achieve better yields and meet organic crop regulatory standards regarding pesticide residue and heavy metals while reducing the use of synthetic or salt-based fertilizers/pesticides. The BioAg package includes fulvic and humic acids, amino acids, plant-available silicon, micronutrients, and microorganism-based solutions. BioAg’s Ful-Power humic acids act as nutrient-chelating agents, improving yield and quality by retaining key plant-supportive compounds such as aromatics, phenolic and carboxylic groups. Cal-Mino amino acids from enzymatically digested non-GMO soybeans offer an organic nitrogen source with carbon backbones that support nutrient formation, suitable for both conventional and organic farming. The company even offers plant-available silicon in dry and liquid forms, suitable for soil and foliar applications. Its product blends, like Bio-SuperSil, combine silicon with humic and fulvic acids to create effects not typically seen in other silicon-based solutions. Additionally, BioAg formulates specialized blends to combat micronutrient deficiencies, improving nutrient availability by complexing and chelating them during production..

Abzena combines deep scientific expertise with a flexible, high-touch approach to help customers bring groundbreaking therapies to market. As a CRO and a CDMO, it integrates design, development and manufacturing under a single organization, supporting the advancement of complex biologics and bioconjugates. This end-to-end approach enables seamless progression from early discovery through phases one, two and three, strengthening regulatory readiness and accelerating the path to commercial manufacturing. Abzena’s specialized services include Antibody-drug conjugates (ADC) and Antibody-oligo conjugates (AOC), bi-specific and multi-specific antibodies, T-cell engagers and radiopharmaceuticals (RDC). Its proprietary linker technology, ThioBridge™ and advanced protein engineering capabilities ensure stability and scalability. The company’s cell line development platform, AbZelectPRO™, also delivers high-impact yields exceeding eight grams per liter before process intensification, ensuring efficiency and scalability as programs progress onwards into downstream development and manufacturing. “One thing that differentiates us as a drug development partner is that we get more involved with companies that may have a single target or a few programs in their pipeline,” says Matt Stober, CEO. “We understand how important these programs are to these companies, and we stay highly engaged with their leadership teams to ensure development moves along at the necessary pace for them to keep moving forward.” Abzena’s customer base is comprised of small and mid-sized biotech companies and large multi-national pharmaceutical firms. Leveraging the deep scientific expertise of its 450+ professionals, including 75 PhDs their global scientific teams work closely with customers to align projects with timelines and product performance goals to ensure a successful outcome. Guiding customers through the Investigational New Drug (IND) submission process is an essential regulatory step at which Abzena excels. Its expertise in IND-enabling work allows customers to enter clinical trials efficiently, helping them reach important milestones in their drug development journey. Delays and risks are minimized by staying ahead of evolving guidelines and incorporating regulatory feedback to ensure that supporting data, development processes, and documentation align with the latest standards. .